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Abstract
Introduction:  Goodpasture's disease is a rare immunological disease with formation of
pathognomonic antibodies against renal and pulmonary basement membranes. Cerebral
involvement has been reported in several cases in the literature, yet the pathogenetic mechanism
is not entirely clear.
Case presentation: A 21-year-old Caucasian man with Goodpasture's disease and end-stage
renal disease presented with two generalized seizures after a period of mild cognitive disturbance.
Blood pressure and routine laboratory tests did not exceed the patient's usual values, and
examination of cerebrospinal fluid was unremarkable. Cerebral magnetic resonance imaging (MRI)
revealed multiple cortical and subcortical lesions on fluid-attenuated inversion recovery sequences.
Since antiglomerular basement membrane antibodies were found to be positive with high titers,
plasmapheresis was started. In addition, cyclophosphamide pulse therapy was given on day 13.
Encephalopathy and MRI lesions disappeared during this therapy, and antiglomerular basement
membrane antibodies were significantly reduced. Previous immunosuppressive therapy was
performed without corticosteroids and terminated early after 3 months.
The differential diagnostic considerations were cerebral vasculitis and posterior reversible
encephalopathy syndrome. Vasculitis could be seen as an extrarenal manifestation of the underlying
disease. Posterior reversible encephalopathy syndrome, on the other hand, can be triggered by
immunosuppressive therapy and may appear without a hypertensive crisis.
Conclusion: A combination of central nervous system symptoms with a positive antiglomerular
basement membrane test in a patient with Goodpasture's disease should immediately be treated
as an acute exacerbation of the disease with likely cross-reactivity of antibodies with the choroid
plexus. In our patient, a discontinuous strategy of immunosuppressive therapy may have favored
recurrence of Goodpasture's disease.
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Introduction
In Goodpasture's disease, a type II hypersensitivity reac-
tion is present with antibody and T-lymphocyte reactivity
to the NC1 domain of the alpha3 chain of type 4 collagen
[1]. These specific antigens exist on the basement mem-
branes of the kidney and pulmonary alveoli [2] but not on
the basal membranes of the brain. However, the antigen
has been found in the choroid plexus [3,4] and it has been
shown that even normal individuals have low titers of
antiglomerular basement membrane (anti-GBM) anti-
bodies [5]. Although NC1 is expressed in the thymus,
CD4+ cells can escape thymic deletion and participate in
the disease. It is postulated that failure to develop toler-
ance to high-affinity peptides from this antigen is likely to
be a consequence of the failure of antigen-presenting cells
[1,6].
The usual treatments for Goodpasture's disease are
administration of cyclophosphamide and prednisolone,
and removal of pathogenic antibodies with plasmapher-
esis, as the activity of the disease correlates with the anti-
body level. The latter has drastically improved the
prognosis and outcome in patients with Goodpasture's
disease [7-9]. Maintaining therapy of oral prednisolone is
recommended for at least 6 months, starting at a dose of
1 mg/kg daily, and continuously reducing it over the fol-
lowing 6 months.
Case presentation
A 21-year-old Caucasian man with histologically proven
(renal biopsy) Goodpasture's disease since spring 2006
was admitted to our hospital after two generalized tonic-
clonic seizures with preceding neuropsychological symp-
toms of decreased alertness and slowed executive func-
tions. The patient was found to be somnolent, with
elevated blood pressure of 180/90 mmHg and a second
generalized seizure. Aspiration during the seizure required
intubation and mechanical ventilation until the third day
after admission.
Regarding his past medical history, the patient was first
treated for a rapid progressive glomerulonephritis
(RPGN) in another hospital when Goodpasture's disease
was diagnosed histologically through renal biopsy (linear
deposition of immunoglobulins along the basement
membrane) and detection of anti-GBM antibodies in the
plasma. A cyclophosphamide pulse therapy was adminis-
tered, but renal disease progressed and hemodialysis
became necessary and the cyclophosphamide therapy was
terminated. One month later, renal replacement therapy
was switched to continuous ambulatory peritoneal dialy-
sis. Four months later, the patient was readmitted because
of a pulmonary complication with anemia due to tracheal
suffusions and microbleeds in combination with a gas-
trointestinal reflux disease. Cyclophosphamide therapy
was reintroduced with monthly administration of 1 g as a
bolus, initially. Immunosuppressive treatment yielded
good elimination of anti-GBM antibodies. However, a
consequent immunosuppressive therapy of at least 6
months duration had never been maintained. In sum-
mary, the patient received three therapy cycles before
admission to our hospital with the central nervous system
symptoms, but neither cyclophosphamide nor steroids
had been given on a regular basis.
Routine laboratory tests showed an elevation of creatinine
(1107 μmol/l, normal value: 72-127 μmol/l) and serum
urea (16.4 mmol/l, normal value: 3.0-9.2 mmol/l), while
blood cell count, electrolytes, blood gas analysis and liver
enzymes were normal. A chest X-ray was consistent with
pneumonia after aspiration. Cranial computed tomogra-
phy was normal. Cerebral magnetic resonance imaging
(MRI) revealed multiple T2- and fluid-attenuated inver-
sion recovery (FLAIR)-hyperintense lesions subcortically,
predominantly located in the posterior dorsal and lateral
white matter as well as in the cerebellar white matter, con-
sistent with cerebral edema (Figures 1 and 2). The lesions
did not enhance contrast media nor did they match a pat-
tern of ischemic infarctions. The time-of-flight angiogra-
phy did not detect vasculitic stenosis.
After extubation, the patient presented a mild psycho-syn-
drome with cognitive slowing and deficits in mnestic
function. Apart from a positive Babinski sign on the left,
his neurological state was normal. Due to the initial pres-
entation with pneumonia, high-dose steroid therapy was
not administered. Since anti-GBM antibodies were ele-
vated (200 U/mL, normal value: <10 U/mL), plasmapher-
esis was started, alternating with continuous veno-venous
hemofiltration. During this therapy, the psycho-syn-
drome resolved and the MR-morphological alterations
almost diminished in parallel (Figure 3). Anti-GBM anti-
bodies scaled down to 21 U/mL after five cycles of plas-
mapheresis initiated at day 6 (substitution of 4 litre
albumin at each session) and one pulse of 1 g cyclophos-
phamide at day 13 (Figure 4). Antinuclear antibodies
were negative at all times. The patient was dismissed in a
neurologically and neuropsychologically healthy condi-
tion under continued oral cyclophosphamide therapy.
Discussion
The three most likely differential diagnoses for this case
were cerebral vasculitis, metabolic encephalopathy, and
posterior reversible encephalopathy syndrome (PRES).
Cerebral vasculitis can occur with antineutrophil cytoplas-
mic antibodies (ANCA)-positive rheumatic diseases such
as Wegener's granulomatosis or systemic lupus erythema-
tosus [10]. In our patient, Goodpasture's disease was his-
tologically established by kidney biopsy and proof of anti-Journal of Medical Case Reports 2009, 3:120 http://www.jmedicalcasereports.com/content/3/1/120
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GBM antibodies in circulation. ANCAs were never posi-
tive. There are case reports in the literature that report
ANCA-negative cerebral vasculitic alterations coinciding
with Goodpasture's disease [11,12], but the mechanism
of cerebral involvement is not entirely clear.
A diagnosis of cerebral vasculitis was supported by the
rapid response to treatment, although it was hampered by
a negative MRI scan and a missing biopsy. Normal vessels
on MRI, though, do not exclude small vessel vasculitis
[13]. A conventional angiography was not performed in
view of the potential side effects and the limited therapeu-
tic consequences.
Differential diagnosis of metabolic encephalopathy
seemed unlikely: liver enzymes were not significantly ele-
vated, renal parameters were within the patient's usual
range, and mistakes in performing peritoneal dialysis
were anamnestically ruled out.
The most likely differential diagnosis for this patient is
PRES. This is characterized by neurological alterations
such as headache, seizures, focal neurological signs, and
cerebral edema of the white matter predominantly in the
posterior parts of the brain. Hypertension, immunosup-
pressive therapy, and uremia may be contributing factors.
The MR-morphological signs of cerebral edema may be
attributed to a loss of cerebral autoregulation [14]. PRES
is more likely in patients with sepsis, and infections with
Gram-positive organisms turned out to be a contributing
factor [15]. Although clinical presentation, coincident
immunosuppression, and the MR-morphological features
match the diagnosis of PRES, no actual cause of the dis-
ease could be found, so this diagnosis was ruled out.
Axial fluid-attenuated inversion recovery sequence upon the patient's admission revealed multiple edematous lesions in sub- cortical and juxtacortical white matter consistent with a vasculitis or posterior reversible encephalopathy syndrome Figure 1
Axial fluid-attenuated inversion recovery sequence upon the patient's admission revealed multiple edematous 
lesions in subcortical and juxtacortical white matter consistent with a vasculitis or posterior reversible enceph-
alopathy syndrome.
(a, b) Contrast enhanced magnetic resonance imaging revealed non-enhancing lesions Figure 2
(a, b) Contrast enhanced magnetic resonance imaging revealed non-enhancing lesions. (c) Time-of-flight angiogra-
phy did not detect cerebral vasculitis and showed normal vessel calibers.Journal of Medical Case Reports 2009, 3:120 http://www.jmedicalcasereports.com/content/3/1/120
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Blood pressure was within the patient's normal range, and
the symptoms and MR-morphological alterations
resolved during plasmapheresis. A bacterium causing the
pneumonia could not be isolated.
Conclusion
In summary, our case is unique in that we took a differen-
tial diagnosis of cerebral vasculitis on the basis of a Good-
pasture's disease into account. In an extensive meta-
analysis for ANCA-associated vasculitides, it has been
shown that pulsed immunosuppressive therapy with
cyclophosphamide has a lower toxicity than continuous
administration of this drug. Pulsed cyclophosphamide
treatment seems to come at the cost of a higher rate of
recurrence [9]. A discontinuous strategy of immunosup-
pressive therapy may have favored recurrence of Goodpas-
ture's disease, and that the cerebral involvement can thus
be seen as the third relapse of the disease.
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